CD28 and cancer: Some researchers suggest that the chronic stimulation of cancer antigens leads to the cycle activation of the immune cells, which eventually causes CD8+CD28− T lymphocytes to proliferate and exert negative regulatory functions, thus inhibiting the tumor-killing effect of CTL (21).